UCAR-T Cells

UCAR-T Cells represent a promising class of allogeneic, off-the-shelf chimeric antigen receptor (CAR) T cell products engineered to overcome host immune rejection, a key challenge in developing universal CAR-T therapies. These cells incorporate various "hypo-immunity" strategies, such as TCR knockout to prevent Graft-versus-Host Disease (GvHD), and modifications to MHC-I and MHC-II expression (e.g., B2M and CIITA knockout) to reduce T cell-mediated rejection. Some variants also include knock-ins of HLA-E and CLEC2D or anti-KIR2D CARs to inhibit NK cell activation. UCAR-T Cells are designed for dual-targeting, specifically against CD19 and BCMA, and have demonstrated potent antitumor activity in preclinical xenograft models. They are currently undergoing clinical evaluation in investigator-initiated trials for conditions such as advanced glioma and relapse/refractory autoimmune diseases.

Other names

Universal CAR-T CellsUniversal Chimeric Antigen Receptor T-cells